Cairo Diagnostics
Cairo Diagnostics is a CLIA/CAP/NYSDOH-certified specialty reference lab in White Plains, NY, providing multi-modality hematopathology diagnostics — including flow cytometry, NGS, FISH, PCR, cytogenetics, and the PsiGenex hereditary cancer panel — to Tri-State hematologists, oncologists, and health systems, now operating as a Sonic Healthcare USA subsidiary.
- Company typePrivate
- Founded2012
- HeadquartersWhite Plains, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cairo Diagnostics does
Cairo Diagnostics is a CLIA-, CAP-, and NYSDOH-certified specialty reference laboratory headquartered in White Plains, NY, focused exclusively on hematopathology. The lab operates a multi-modality diagnostic stack spanning morphology and immunohistochemistry, 15-color flow cytometry, FISH, PCR, cytogenetics, and next-generation sequencing, supported by a clinical team of MD/PhD hematopathologists trained at MD Anderson, NYU, and Columbia and a publication record exceeding 115 peer-reviewed papers. Sub-brands include PsiGenex, a 54-gene hereditary cancer panel that extends the franchise into germline oncology testing.
The business serves community and academic hematologists, oncologists, and health systems across the New York/New Jersey/Connecticut Tri-State area, with named customers including New York-Presbyterian, White Plains Medical Group, WestMed, Crystal Run, and ProHealth. Order intake runs through online portals and bidirectional EMR integration, and the lab offers seven-days-a-week same-day STAT turnaround for time-sensitive oncology workups. Revenue mechanics follow the standard U.S. specialty reference lab model: third-party reimbursement (Medicare/Medicaid/commercial payers) per test, with consultative hematopathology services billed as professional components.
In November 2025 the company was acquired by Sonic Healthcare USA (via ProPath Services, LLC), converting Cairo from an independent regional operator into a subsidiary within one of the three largest U.S. laboratory networks. The strategic intent is to retain the hematopathology specialty franchise while leveraging Sonic's national logistics, payer contracts, and broader test menu.
Cairo Diagnostics firmographics
Firmographics- Name
- Cairo Diagnostics
- Legal name
- Cairo Diagnostics, LLC
- Website
- https://cairodiagnostics.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cairo Diagnostics is a CLIA/CAP/NYSDOH-certified specialty reference lab in White Plains, NY, providing multi-modality hematopathology diagnostics — including flow cytometry, NGS, FISH, PCR, cytogenetics, and the PsiGenex hereditary cancer panel — to Tri-State hematologists, oncologists, and health systems, now operating as a Sonic Healthcare USA subsidiary.
- Ownership category
- akta.pro rank
Cairo Diagnostics industry classification
Industry- Product category
- Diagnostic Laboratory Services — Hematopathology & Molecular Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Hematology & Coagulation Laboratories (HLAFAMAC)
- akta.pro secondary industries
- Hematologic Oncology (Leukemia/Lymphoma/Myeloma) (HLAKAFAD), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Hematology & Coagulation Diagnostics (HLAHAAAB)
Keywords
Where Cairo Diagnostics is headquartered
LocationHeadquarters
- HQ city
- White Plains
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cairo Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Laboratory Diagnostic Testing Services: Cairo Diagnostics generates revenue through specialized hematopathology and molecular diagnostic testing services provided to referring physicians, hospitals, and academic medical centers. Services include consultation, NGS, flow cytometry, FISH, PCR, cytogenetics, and morphology/IHC testing. The company accepts all commercial insurance plans and Medicare, with a financial hardship program for uninsured or underinsured patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance-based laboratory testing services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Cairo Diagnostics product offering
Product offeringCore offering
Cairo Diagnostics is a specialized hematopathology reference laboratory providing molecular profiling and diagnostic interpretation for blood cancers (leukemias, lymphomas, myelomas), bone marrow disorders, lymph node biopsies, and solid tumors. The company delivers comprehensive consults rather than raw test results, combining NGS, 15-color flow cytometry, FISH/cytogenetics, PCR, and morphology/IHC services with on-demand board-certified hematopathologist consultation.
Product overview
Cairo Diagnostics is a specialized hematopathology laboratory offering a comprehensive diagnostic testing portfolio focused on blood cancers and solid tumor molecular profiling. The company's offerings include consultative pathology services (primary and second opinion consultations), advanced molecular testing (NGS, solid tumor profiling, PCR), cytogenetics/FISH analysis, 15-color flow cytometry, and morphology/IHC services. The company also operates PsiGenex as a subsidiary sub-brand focused on hereditary cancer germline mutation testing. Services are designed for hematologists, oncologists, pathologists, hospitals, and academic centers, with turnaround times including same-day STAT results, 24-hour Flow Cytometry, and FISH 24/48 hour turnaround for most cases.
Differentiator
Problem solved
Functional benefit
Brands
- PsiGenex: A subsidiary brand for testing germline mutations, offering a comprehensive hereditary cancer panel that covers 54 genes associated with increased susceptibility to many cancers.
Quantifiable outcome
- 24-48 hour FISH turnaround vs industry standard
- +4 more outcomes
Companies that use Cairo Diagnostics
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Cairo Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Cairo Diagnostics partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Cairo Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Quest Diagnostics: One of the two largest U.S. reference laboratories, offering broad hematology, molecular, and oncology testing including NGS and flow cytometry; competes with Cairo for hospital and oncology referrals across the Tri-State.
- Laboratory Corporation of America (Labcorp): Large national reference laboratory with a substantial hematology/oncology menu including molecular profiling; competes for the same hospital and community-oncology referral base, with materially greater scale and payor leverage.
- Foundation Medicine: Specialized molecular profiling service for solid tumors and hematologic malignancies using comprehensive NGS assays; overlaps Cairo's NGS solid-tumor and disease-focused panel offerings for oncologists seeking genomic profiling.
- ARUP Laboratories: Academic-affiliated national reference laboratory offering an extensive hematopathology and molecular diagnostics menu; competes for academic medical center and complex-case referrals.
Direct peers
- CBLPath: Specialty anatomic and hematopathology laboratory and historical Sonic Healthcare USA subsidiary, directly comparable to Cairo Diagnostics; several Cairo senior leaders (VP Operations, Laboratory Manager) were previously CBLPath executives.
- NeoGenomics Laboratories: Specialty oncology and hematopathology reference laboratory offering NGS, flow cytometry, FISH, and cytogenetics — directly overlapping Cairo's core service menu and target customer base of community oncologists and hospitals.
- Caris Life Sciences: Molecular profiling laboratory offering comprehensive NGS, whole-exome, and IHC-based testing for solid and hematologic cancers; competes with Cairo in molecular oncology profiling for community oncologists.
- siParadigm Diagnostics: Specialty hematopathology and molecular diagnostics laboratory where Cairo's Director of Sales & Marketing previously served as National Sales Manager; direct overlap in leukemia/lymphoma flow cytometry and molecular profiling services.
Emerging players
- Invitae: Genetic testing company with a hereditary cancer panel portfolio directly comparable to PsiGenex, Cairo's hereditary cancer sub-brand; overlaps in germline cancer risk assessment for high-risk patients and oncologists.
- Guardant Health: Specialized oncology genomics company focused on liquid biopsy and molecular profiling; competes for advanced molecular testing referrals in oncology, with a particularly differentiated approach to non-invasive tumor profiling.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Cairo Diagnostics social profiles
Digital presenceCairo Diagnostics compliance and trust
Trust signalCompliance3 records
Cairo Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cairo Diagnostics leadership team
Management profileNumber of profiles
Profiles9 records
Cairo Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Cairo Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cairo Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cairo Diagnostics
What does Cairo Diagnostics do?
Cairo Diagnostics is a specialized hematopathology reference laboratory providing molecular profiling and diagnostic interpretation for blood cancers (leukemias, lymphomas, myelomas), bone marrow disorders, lymph node biopsies, and solid tumors. The company delivers comprehensive consults rather than raw test results, combining NGS, 15-color flow cytometry, FISH/cytogenetics, PCR, and morphology/IHC services with on-demand board-certified hematopathologist consultation.
Is Cairo Diagnostics a public or private company?
Cairo Diagnostics is a private company. It is classified as corporate owned and is currently operating.
When was Cairo Diagnostics founded?
Cairo Diagnostics was founded in 2012. It employs 11 to 50 people.
Where is Cairo Diagnostics based?
Cairo Diagnostics is headquartered in White Plains, United States, in the North America region.
How does Cairo Diagnostics make money?
One revenue line is on record: laboratory Diagnostic Testing Services.
Who are Cairo Diagnostics's main competitors?
Broad incumbents on record are Quest Diagnostics, Laboratory Corporation of America (Labcorp), Foundation Medicine and ARUP Laboratories. Direct peers are CBLPath, NeoGenomics Laboratories, Caris Life Sciences and siParadigm Diagnostics. Emerging players are Invitae and Guardant Health.
Does Cairo Diagnostics have an API?
No public API is recorded for Cairo Diagnostics.
What industry is Cairo Diagnostics in?
Cairo Diagnostics's product category is Diagnostic Laboratory Services — Hematopathology & Molecular Diagnostics. Its primary akta.pro industry code is HLAFAMAC, Hematology & Coagulation Laboratories, with a secondary code of HLAKAFAD, Hematologic Oncology (Leukemia/Lymphoma/Myeloma). Its NAICS code is 621511 and its SIC code is 8071.